Nikoletta Fotaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8055612/publications.pdf

Version: 2024-02-01

94 papers	1,806 citations	331670 21 h-index	315739 38 g-index
97 all docs	97 docs citations	97 times ranked	1806 citing authors

#	Article	IF	Citations
1	Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspectsâ€. Journal of Pharmacy and Pharmacology, 2010, 56, 453-462.	2.4	206
2	Paediatric oral biopharmaceutics: Key considerations and current challenges. Advanced Drug Delivery Reviews, 2014, 73, 102-126.	13.7	104
3	Biorelevant Dissolution Methods and Their Applications in In Vitro- In Vivo Correlations for Oral Formulations~!2009-09-14~!2009-11-02~!2010-04-29~!. Open Drug Delivery Journal, 2010, 4, 2-13.	2.0	89
4	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
5	Biopharmaceutical aspects and implications of excipient variability in drug product performance. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 111, 1-15.	4.3	75
6	A comparative study of different release apparatus in generating in vitroâ€“in vivo correlations for extended release formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 73, 115-120.	4.3	59
7	Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. Journal of Controlled Release, 2015, 210, 189-197.	9.9	59
8	Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. European Journal of Pharmaceutical Sciences, 2020, 143, 105170.	4.0	58
9	In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. European Journal of Pharmaceutical Sciences, 2005, 24, 115-122.	4.0	53
10	Impact of gastrointestinal disease states on oral drug absorption â€“ implications for formulation design â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 674-698.	2.4	53
11	Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration. European Journal of Pharmaceutical Sciences, 2005, 26, 324-333.	4.0	48
12	Assessment of Age-Related Changes in Pediatric Gastrointestinal Solubility. Pharmaceutical Research, 2016, 33, 52-71.	3.5	48
13	Flow-Through Cell Apparatus (USP Apparatus 4): Operation and Features. Dissolution Technologies, 2011, 18, 46-49.	0.6	47
14	Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer. International Journal of Pharmaceutics, 2013, 453, 380-388.	5.2	42
15	Biorelevant Dissolution: Methodology and Application in Drug Development. Dissolution Technologies, 2009, 16, 6-12.	0.6	42
16	Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 491-505.	3.3	39
17	<scp>BU</scp>08073 a buprenorphine analogue with partial agonist activity at Î¼â€receptors in vitro but longâ€lasting opioid antagonist activity in vivo in mice. British Journal of Pharmacology, 2015, 172, 668-680.	5.4	32
18	Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products â€“ a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 603-642.	2.4	29

#	Article	IF	Citations
19	The Flow Through Cell Methodology in the Evaluation of Intralumenal Drug Release Characteristics. Dissolution Technologies, 2005, 12, 17-21.	0.6	27
20	Considerations for the development of in vitro dissolution tests to reduce or replace preclinical oral absorption studies. European Journal of Pharmaceutical Sciences, 2017, 99, 193-201.	4.0	22
21	Recommended strategies for the oral administration of paediatric medicines with food and drinks in the context of their biopharmaceutical properties: a review. Journal of Pharmacy and Pharmacology, 2017, 69, 384-397.	2.4	22
22	Fed-state gastric media and drug analysis techniques: Current status and points to consider. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 234-248.	4.3	21
23	Surface Dissolution UV Imaging for Investigation of Dissolution of Poorly Soluble Drugs and Their Amorphous Formulation. AAPS PharmSciTech, 2019, 20, 113.	3.3	20
24	Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products. AAPS Journal, 2020, 22, 47.	4.4	19
25	Mechanistic Understanding of the Effect of PPIs and Acidic Carbonated Beverages on the Oral Absorption of Itraconazole Based on Absorption Modeling with Appropriate in Vitro Data. Molecular Pharmaceutics, 2013, 10, 4016-4023.	4.6	18
26	Interpolymer Complexes of EudragitÂ® Copolymers as Novel Carriers for Colon-Specific Drug Delivery. Polymers, 2020, 12, 1459.	4.5	18
27	Towards the development of a paediatric biopharmaceutics classification system: Results of a survey of experts. International Journal of Pharmaceutics, 2016, 511, 1151-1157.	5.2	17
28	Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. Journal of Pharmacy and Pharmacology, 2010, 58, 827-836.	2.4	16
29	Small-Scale Assays for Studying Dissolution of Pharmaceutical Cocrystals for Oral Administration. AAPS PharmSciTech, 2016, 17, 245-251.	3.3	16
30	Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review. Journal of Pharmacy and Pharmacology, 2019, 71, 699-723.	2.4	16
31	Rationale for Selection of Dissolution Media: Three Case Studies. Dissolution Technologies, 2013, 20, 6-13.	0.6	16
32	Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, 2019, 18, 279-283.	2.2	14
33	Highly Water-Soluble Orotic Acid Nanocrystals Produced by High-Energy Milling. Journal of Pharmaceutical Sciences, 2019, 108, 1848-1856.	3.3	14
34	Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam. British Journal of Clinical Pharmacology, 2019, 85, 1728-1739.	2.4	14
35	Impact of Magnesium Stearate Presence and Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. AAPS Journal, 2020, 22, 75.	4.4	13
36	An in vitroâ€“in vivo correlation study for nifedipine immediate release capsules administered with water, alcoholic and non-alcoholic beverages: Impact of in vitro dissolution media and hydrodynamics. International Journal of Pharmaceutics, 2016, 499, 330-342.	5.2	12

#	Article	IF	Citations
37	In Vitroâ€“In Vivo Correlations Based on In Vitro Dissolution of Parent Drug Diltiazem and Pharmacokinetics of its Metabolite. Pharmaceutics, 2019, 11, 344.	4.5	12
38	Co-administration of Paediatric Medicines with Food and Drinks in the Context of Their Physicochemical Propertiesâ€”a Global Perspective on Practices and Recommendations. AAPS Journal, 2020, 22, 54.	4.4	12
39	Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance: Part 1â€”Effects on Solubility of Poorly Soluble Drugs. AAPS PharmSciTech, 2020, 21, 177.	3.3	12
40	Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties. Case Study: Superdisintegrants. AAPS Journal, 2020, 22, 46.	4.4	12
41	Pros and cons of methods used for the prediction of oral drug absorption. Expert Review of Clinical Pharmacology, 2009, 2, 195-208.	3.1	11
42	Effects of medicines used to treat gastrointestinal diseases on the pharmacokinetics of coadministered drugs: a PEARRL Review. Journal of Pharmacy and Pharmacology, 2019, 71, 643-673.	2.4	11
43	On the Design of Food Effect Studies in Adults for Extrapolating Oral Drug Absorption Data to Infants: an Exploratory Study Highlighting the Importance of Infant Food. AAPS Journal, 2020, 22, 6.	4.4	11
44	Survey Results for In Vitro-In Vivo Correlations (IVIVC): Critical Variables for Success. Dissolution Technologies, 2013, 20, 48-50.	0.6	11
45	Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 491-505.	3.3	11
46	Understanding and predicting the impact of critical dissolution variables for nifedipine immediate release capsules by multivariate data analysis. International Journal of Pharmaceutics, 2017, 518, 41-49.	5.2	10
47	Strategic drug analysis in fed-state gastric biorelevant media based on drug physicochemical properties. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 326-341.	4.3	10
48	Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 154, 195-209.	4.3	10
49	The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets. European Journal of Pharmaceutical Sciences, 2020, 155, 105534.	4.0	10
50	Surface dissolution UV imaging for characterization of superdisintegrants and their impact on drug dissolution. International Journal of Pharmaceutics, 2020, 577, 119080.	5.2	10
51	Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions. AAPS Journal, 2020, 22, 126.	4.4	9
52	Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations. AAPS PharmSciTech, 2020, 21, 287.	3.3	9
53	In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants. AAPS PharmSciTech, 2020, 21, 282.	3.3	9
54	A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111097.	5.0	9

#	Article	IF	Citations
55	Gastrointestinal diseases and their impact on drug solubility: Crohn's disease. European Journal of Pharmaceutical Sciences, 2020, 152, 105459.	4.0	8
56	Biopharmaceutical Understanding of Excipient Variability on Drug Apparent Solubility Based on Drug Physicochemical Properties: Case Studyâ€"Hypromellose (HPMC). AAPS Journal, 2020, 22, 49.	4.4	8
57	Predicting budesonide performance in healthy subjects and patients with Crohn's disease using biorelevant in vitro dissolution testing and PBPK modeling. European Journal of Pharmaceutical Sciences, 2021, 157, 105617.	4.0	8
58	Investigating the Impact of Crohnâ€™s Disease on the Bioaccessibility of a Lipid-Based Formulation with an In Vitro Dynamic Gastrointestinal Model. Molecular Pharmaceutics, 2021, 18, 1530-1543.	4.6	8
59	Sex- and smoke-related differences in gastrointestinal transit of cyclosporin A microemulsion capsules. European Journal of Pharmaceutical Sciences, 2014, 63, 140-146.	4.0	7
60	In Vivo Predictive Dissolution and Simulation Workshop Report: Facilitating the Development of Oral Drug Formulation and the Prediction of Oral Bioperformance. AAPS Journal, 2018, 20, 100.	4.4	7
61	Biorelevant release testing of biodegradable microspheres intended for intra-articular administration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 139, 115-122.	4.3	7
62	Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 2022, 169, 106097.	4.0	7
63	Parameterization of small intestinal water volume using PBPK modeling. European Journal of Pharmaceutical Sciences, 2015, 67, 55-64.	4.0	6
64	Factors Affecting Successful Extrapolation of Ibuprofen Exposure from Adults to Pediatric Populations After Oral Administration of a Pediatric Aqueous Suspension. AAPS Journal, 2020, 22, 146.	4.4	6
65	In Vitro and In Silico ADME Prediction. , 2018, , 301-330.		5
66	BCS-based biowaivers: Extension to paediatrics. European Journal of Pharmaceutical Sciences, 2020, 155, 105549.	4.0	5
67	Gastrointestinal diseases and their impact on drug solubility: Ulcerative Colitis. European Journal of Pharmaceutical Sciences, 2020, 152, 105458.	4.0	5
68	Investigation of drug partition kinetics to fat in simulated fed state gastric conditions based on drug properties.. European Journal of Pharmaceutical Sciences, 2020, 146, 105263.	4.0	5
69	In vitro - in vivo relations for the parenteral liposomal formulation of Amphotericin B: A clinically relevant approach with PBPK modeling. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 159, 177-187.	4.3	5
70	In vitro in vivo relations for the parenteral liposomal formulation of Amphotericin B: A biorelevant and clinically relevant approach. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 159, 188-197.	4.3	5
71	Preliminary pharmacokinetic study of the anticancer 6BIO in mice using an UHPLC-MS/MS approach. Journal of Pharmaceutical and Biomedical Analysis, 2019, 164, 317-325.	2.8	4
72	Gastrointestinal diseases and their impact on drug solubility: Celiac disease. European Journal of Pharmaceutical Sciences, 2020, 152, 105460.	4.0	4

#	Article	IF	Citations
73	Investigation and simulation of dissolution with concurrent degradation under healthy and hypoalbuminaemic simulated parenteral conditions- case example Amphotericin B. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 423-431.	4.3	3
74	In vitro conditions for performance evaluation of products for intravascular administration: Developing appropriate test media using Amphotericin B as a model drug. European Journal of Pharmaceutical Sciences, 2020, 143, 105174.	4.0	3
75	Sex-related in vitro/in vivo and PK/PD correlations after oral single dose furosemide administration. Journal of Pharmaceutical Technology & Drug Research, 2016, 5, 2.	1.0	3
76	Affinity of Lipophilic Drugs to Mixed Lipid Aggregates in Simulated Gastrointestinal Fluids. Journal of Pharmaceutical Sciences, 2021, 110, 186-197.	3.3	2
77	Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling. Journal of Pharmaceutical Sciences, 2021, 110, 3874-3888.	3.3	2
78	Dissolution Highlights from the 2015 AAPS Annual Meeting in Orlando. Dissolution Technologies, 2016, 23, 42-47.	0.6	2
79	Performance Evaluation of Montelukast Pediatric Formulations: Part II â€" a PBPK Modelling Approach. AAPS Journal, 2022, 24, 27.	4.4	2
80	Impact of presence of excipients in drug analysis in fed-state gastric biorelevant media. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 131, 178-188.	4.3	1
81	Highlights from the 2020 AAPS 360 Annual Meeting. Dissolution Technologies, 2021, 28, 36-40.	0.6	1
82	Evaluating pediatric and adult simulated fluids solubility: Abraham solvation parameters and multivariate analysis. Pharmaceutical Research, 2021, 38, 1889.	3.5	1
83	Performance Evaluation of Montelukast Pediatric Formulations: Part Iâ€"Age-Related In Vitro Conditions. AAPS Journal, 2022, 24, 26.	4.4	1
84	Influence of Sex and Food on the Bioavailability and the R-to-S Conversion of Ketoprofen Stereoisomers in Humans. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 167-169.	1.6	0
85	Using in silico process simulation tools in pharmacy education: Considerations for pivoting to online learning. Pharmacy Education, 0, , 124-135.	0.6	0
86	2010 Pharmaceutical Sciences World Congress Provides Dissolution Programming with an International Flavor. Dissolution Technologies, 2011, 18, 38-42.	0.6	0
87	Dissolution Highlights from the 2011 AAPS Annual Meeting in Washington, D. C.. Dissolution Technologies, 2012, 19, 69-70.	0.6	0
88	Dissolution Highlights from the 2012 AAPS Annual Meeting in Chicago. Dissolution Technologies, 2013, 20, 57-59.	0.6	0
89	Dissolution Highlights from the 2013 AAPS Annual Meeting in San Antonio. Dissolution Technologies, 2014, 21, 44-46.	0.6	0
90	Dissolution Highlights from the 2014 AAPS Annual Meeting in San Diego. Dissolution Technologies, 2015, 22, 56-58.	0.6	0

#	Article	IF	Citations
91	Meeting Report: AAPSâ€“NIFDC Joint Workshop on Dissolution Testing, Biowaiver, and Bioequivalence. Dissolution Technologies, 2016, 23, 46-55.	0.6	0
92	Dissolution Highlights from the 2016 AAPS Annual Meeting in Denver. Dissolution Technologies, 2017, 24, 68-72.	0.6	0
93	Dissolution Highlights from the 2017 AAPS Annual Meeting in San Diego. Dissolution Technologies, 2018, 25, 78-83.	0.6	0
94	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis. Pharmaceutics, 2022, 14, 356.	4.5	0